Drug Trial Radar · NCT04931654
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Actual
Start
Sep 28, 2021
Primary completion
Dec 4, 2024
Study completion Aug 12, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
AZD7789Drug
anti-PD-1 and anti-TIM-3 bispecific antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)Time frame: From time of Informed Consent to 90 days post last dose of study intervention
- Number of participants with dose-limiting toxicity (DLT), as defined in the protoocolTime frame: From the first patient until the end of the dose escalation period; approximately 18 months.
- Preliminary anti-tumour activity of AZD7789Time frame: From first participant until last participant assessment; a duration of approximately 4 years. Disease assessments will be performed until progression or initiation of another anticancer therapy.
Locations
21 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Atlanta, Georgia
Research Site
Fort Wayne, Indiana
Research Site
New York, New York
Research Site
Nashville, Tennessee
Research Site
Toronto, Ontario, Canada
Research Site
Beijing, China
Research Site
Guangzhou, China
Research Site
Bordeaux, France
Research Site
Rennes, France
Research Site
Villejuif, France
Research Site
Tbilisi, Georgia
Research Site
Chūōku, Japan
Research Site
Kashiwa, Japan
Research Site
Chisinau, Moldova
Research Site
Amsterdam, Netherlands
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Ankara, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Cordaleo, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.